Comparison of Serum 25(OH) Vitamin D, Parathormone and Immunity Marker Concentrations Between Dogs with Transmissible Venereal Tumour and Healthy Dogs

Overview

Journal Vet Med Sci

Specialty Veterinary Medicine

Date 2023 Aug 3

PMID 37534440

Authors

Helia Kamali Sadeghian

Mehrdad Mohri

Affiliations

Soon will be listed here.

Abstract

Background: 1,25-Dihydroxyvitamin D (1,25(OH) D) is vital in the homeostasis of calcium and bone health as well as in the prevention of many disorders such as neoplasms. Epidemiological data show that low concentrations of both 1,25(OH) D and its precursor 25(OH) vitamin D (25(OH)D) are associated with an increased risk of a variety of human tumours.

Objectives: To investigate 25(OH)D, parathormone (PTH) and immunity marker concentrations in dogs with transmissible venereal tumour (TVT).

Methods: 25(OH)D, PTH and various biochemical and immunity markers were evaluated in dogs with TVT (n = 26) and in healthy (n = 30) dogs.

Results: 25(OH)D concentrations were significantly lower in dogs with TVT in comparison with healthy dogs. In contrast, PTH, immunoglobulin G and interleukin (IL)-9 concentrations were higher in the dogs with TVT. Other variables, including IL-10, interferon γ, calcium and inorganic phosphate, were not statistically different between the two groups.

Conclusions: Decreased serum 25(OH)D concentration may be a risk factor for the development of canine TVT; however, cause-and-effect remains incompletely understood. Further studies are required to elucidate the exact role of 25(OH)D in canine TVT and whether vitamin D supplementation may be useful prophylactically or as an adjunct to chemotherapy.

Citing Articles

Connection between nutrition and oncology in dogs and cats: perspectives, evidence, and implications-a comprehensive review.

Amaral A, Finardi G, Marchi P, de Oliveira N, Principe L, Teixeira N Front Vet Sci. 2025; 11:1490290.

PMID: 40046187 PMC: 11881598. DOI: 10.3389/fvets.2024.1490290.

Vitamin D status in female dogs with mammary gland tumors.

Pineda C, Raya A, Morgaz J, Sanchez-Cespedes R, Millan Y, Aguilera-Tejero E J Vet Intern Med. 2024; 38(4):2257-2264.

PMID: 38946311 PMC: 11256186. DOI: 10.1111/jvim.17137.

Comparison of serum 25(OH) vitamin D, parathormone and immunity marker concentrations between dogs with transmissible venereal tumour and healthy dogs.

Sadeghian H, Mohri M Vet Med Sci. 2023; 9(5):2026-2031.

PMID: 37534440 PMC: 10508550. DOI: 10.1002/vms3.1235.

References

Parker V, Harjes L, Dembek K, Young G, Chew D, Toribio R . Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease. J Vet Intern Med. 2017; 31(3):791-798. PMC: 5435068. DOI: 10.1111/jvim.14653. View

How K, Hazewinkel H, Mol J . Dietary vitamin D dependence of cat and dog due to inadequate cutaneous synthesis of vitamin D. Gen Comp Endocrinol. 1994; 96(1):12-8. DOI: 10.1006/gcen.1994.1154. View

Abu El Maaty M, Wolfl S . Vitamin D as a Novel Regulator of Tumor Metabolism: Insights on Potential Mechanisms and Implications for Anti-Cancer Therapy. Int J Mol Sci. 2017; 18(10). PMC: 5666865. DOI: 10.3390/ijms18102184. View

Rassnick K, Muindi J, Johnson C, Balkman C, Ramnath N, Yu W . In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. Cancer Chemother Pharmacol. 2008; 62(5):881-91. PMC: 2715945. DOI: 10.1007/s00280-008-0678-x. View

Kaewsakhorn T, Kisseberth W, Capen C, Hayes K, Calverley M, Inpanbutr N . Effects of calcitriol, seocalcitol, and medium-chain triglyceride on a canine transitional cell carcinoma cell line. Anticancer Res. 2005; 25(4):2689-96. View

Gerber B, Hauser B, Reusch C . Serum levels of 25-hydroxycholecalciferol and 1,25-dihydroxycholecalciferol in dogs with hypercalcaemia. Vet Res Commun. 2004; 28(8):669-80. DOI: 10.1023/b:verc.0000045954.71403.74. View

Zhang L, Hu S, Korteweg C, Chen Z, Qiu Y, Su M . Expression of immunoglobulin G in esophageal squamous cell carcinomas and its association with tumor grade and Ki67. Hum Pathol. 2011; 43(3):423-34. DOI: 10.1016/j.humpath.2011.05.020. View

Russell D, Rassnick K, Erb H, Vaughan M, McDonough S . An immunohistochemical study of vitamin D receptor expression in canine cutaneous mast cell tumours. J Comp Pathol. 2010; 143(2-3):223-6. DOI: 10.1016/j.jcpa.2010.01.019. View

Weidner N, Woods J, Conlon P, Meckling K, Atkinson J, Bayle J . Influence of Various Factors on Circulating 25(OH) Vitamin D Concentrations in Dogs with Cancer and Healthy Dogs. J Vet Intern Med. 2017; 31(6):1796-1803. PMC: 5697176. DOI: 10.1111/jvim.14834. View

10.

Hurst E, Homer N, Mellanby R . Vitamin D Metabolism and Profiling in Veterinary Species. Metabolites. 2020; 10(9). PMC: 7569877. DOI: 10.3390/metabo10090371. View

11.

Malone E, Rassnick K, Wakshlag J, Russell D, Al-Sarraf R, Ruslander D . Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. Vet Comp Oncol. 2010; 8(3):209-20. DOI: 10.1111/j.1476-5829.2010.00223.x. View

12.

Laing C, Malik R, Wigney D, Fraser D . Seasonal vitamin D status of Greyhounds in Sydney. Aust Vet J. 1999; 77(1):35-8. DOI: 10.1111/j.1751-0813.1999.tb12425.x. View

13.

McCullough M, Weinstein S, Freedman D, Helzlsouer K, Flanders W, Koenig K . Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010; 172(1):21-35. PMC: 2892536. DOI: 10.1093/aje/kwq113. View

14.

Amber E, Henderson R, Adeyanju J, Gyang E . Single-drug chemotherapy of canine transmissible venereal tumor with cyclophosphamide, methotrexate, or vincristine. J Vet Intern Med. 1990; 4(3):144-7. DOI: 10.1111/j.1939-1676.1990.tb00887.x. View

15.

Sadeghian H, Mohri M . Comparison of serum 25(OH) vitamin D, parathormone and immunity marker concentrations between dogs with transmissible venereal tumour and healthy dogs. Vet Med Sci. 2023; 9(5):2026-2031. PMC: 10508550. DOI: 10.1002/vms3.1235. View

16.

Konety B, Lavelle J, Pirtskalaishvili G, Dhir R, Meyers S, Nguyen T . Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol. 2000; 165(1):253-8. DOI: 10.1097/00005392-200101000-00074. View

17.

Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H . Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther. 2009; 30(2):113-25. DOI: 10.1111/j.1365-2036.2009.04022.x. View

18.

Wan J, Wu Y, Huang L, Tian Y, Ji X, Abdelaziz M . ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8 T cells. Cancer Lett. 2021; 502:34-43. DOI: 10.1016/j.canlet.2021.01.002. View

19.

Toyota N, Sakai H, Takahashi H, Hashimoto Y, Iizuka H . Inhibitory effect of 1 alpha,25-dihydroxyvitamin D3 on mast cell proliferation and A23187-induced histamine release, also accompanied by a decreased c-kit receptor. Arch Dermatol Res. 1996; 288(11):709-15. DOI: 10.1007/BF02505282. View

20.

Lappe J, Travers-Gustafson D, Davies K, Recker R, Heaney R . Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007; 85(6):1586-91. DOI: 10.1093/ajcn/85.6.1586. View